Paloma Menendez Valladares

Dr. Paloma Menendez Valladares


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
PVPaloma Menendez Valladares
Paloma Menendez Valladares
MSMaria Isabel Garcia Sanchez
Maria Isabel Garcia Sanchez
MMMyriam Adorna Martínez
Myriam Adorna Martínez
JHJosé-Ángel Hernández-Rivas
José-Ángel Hernández-Rivas
CGCarmen Bermudo Guitarte
Carmen Bermudo Guitarte
GAGuillermo Izquierdo Ayuso
Guillermo Izquierdo Ayuso

28 November 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JHJosé-Ángel Hernández-Rivas
José-Ángel Hernández-Rivas
CGCarmen Bermudo Guitarte
Carmen Bermudo Guitarte
PVPaloma Menendez Valladares
Paloma Menendez Valladares
JNJohanna Carolina Rojas Noboa
Johanna Carolina Rojas Noboa
KKKrysta Kestler
Krysta Kestler
RMRafael Duro Millán
Rafael Duro Millán
The outcome for patients with Multiple Myeloma (MM) is highly variable, therefore, the existence of robust and easy to determine prognostic markers is extremely important for an efficient management of these patients. Presently, there is a debate about the role of the serum free light chains (sFLC) in the prognosis of MM patients both at diagnosis and after treatment. The aim of this study is to evaluate in a cohort of newly diagnosed MM patients from the Southern area of Spain, the prognostic value of sFLC both at baseline and after treatment. 180 patients with a median age of 69 years were followed-up for a median time of 35 (18–61) months. The sFLC ratio (sFLCR) was calculated using the monoclonal sFLC as numerator. Patients were divided in two groups according to a sFLCR cut-off based on ROC analysis. The primary endpoints were the Overall Survival (OS) and the Progression-free Survival (PFS). Additionally, thirty-six MM patients treated with novel agents (Bortezomib/Dexamethasone) that achieved Complete Response (CR) or stringent CR (sCR) before autologous stem cell transplantation were studied to assess the impact of sCR in Disease Free Survival (DFS) and OS. During follow-up there were 72 disease-related deaths. The 5-years OS for the whole group was 51%. However, separate analysis of patients with sFLCR above (group “high”) or below (groups “low”) the cut-off value of 47 shows an OS of 23% and 73%, respectively (HR = 5.03, 95%CI 2.99–8.50, p<0.001). In addition, analysis by ISS stage, showed that the presence of high sFLCR was always significantly associated with a worse OS. Multivariate analysis identified sFLCR (HR = 4.42, 95%CI 2.57–7.60, p<0.001) and beta-2-microglobulin (B2M) (HR = 3.04, 95%IC 1.75–5.31, p3.5 mg/L provided a statistically more significant result for this cohort when compared with the conventional ISS system. The HR for the new model were 2.84 (95% CI, 1.39–5.79, p = 0.004) for patients in stage 2 and 15.39 (95% CI, 6.35–37.33, p<0.001) for those in stage 3. Finally, in the group of patients reaching CR (19/36) or sCR (17/36) after induction, the median DFS for CR patients was 29 months, and NR for sCR patients (HR = 3.73; 95% CI 1.15–12.13, p = 0.03). Importantly, achieving sCR also translated into a significantly longer OS (5y-OS: sCR-89% versus CR-49%; p = 0.003; OS: sCR-NR versus CR-52 months). Our findings confirm the observations that the sFLCR has a major role in the survival of MM patients. A cut-off of sFLCR≥47 was shown to have an independent prognostic value at diagnosis, and a proposed “New Staging System” allows an accurate and simple method to risk stratify MM patients. Furthermore, because achievement of sCR was shown to represent a response state deeper than conventional CR resulting in greater OS and DFS, our study supports the continuity of sFLC ratio as part of the response criteria for MM patients.

1 September 2015 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PVPaloma Menendez Valladares
Paloma Menendez Valladares
MGMi García-Sánchez
Mi García-Sánchez
PBP Cuadri Benítez
P Cuadri Benítez
MLM Lucas
M Lucas
MMM Adorna Martínez
M Adorna Martínez
GAG Izquierdo Ayuso
G Izquierdo Ayuso
Multiple sclerosis (MS) initiates with a first attack or clinically isolated syndrome (CIS). The importance of an early treatment in MS leads to the search, as soon as possible, for novel biomarkers which can predict conversion from CIS to MS. The purpose of this study was to assess the predictive value of the kappa index (κ index), using kappa free light light chains (κ FLCs) in cerebrospinal fluid (CSF), for the conversion of CIS patients to MS, and compare its accuracy with other parameters used in clinical practice. FLC levels were analysed in CSF from 176 patients: 70 as control group, 77 CIS, and 29 relapsing–remitting MS. FLC levels were quantified by nephelometry. κ Index sensitivity and specificity (93.1%; 95.7%) was higher than those from the immunoglobulin G (IgG) index (75.9%; 94.3%), and lower than those from oligoclonal IgG bands (OCGBs) (96.5%; 98.6%). The optimal cut-off for κ index was 10.62. Most of the CIS patients with κ index >10.62 presented OCGBs, IgG index >0.56 and fulfilled magnetic resonance imaging (MRI) criteria. CIS patients above κ index cut-off of 10.62 present 7.34-fold risk of conversion to MS than CIS below this value. The κ index correlated with positive OCGBs, IgG index above 0.56 and MRI criteria.

14 May 2016 in Practical Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JMJosé María Maesa
José María Maesa
PFPatricia Fernández-Riejos
Patricia Fernández-Riejos
CMCatalina Sánchez Mora
Catalina Sánchez Mora
MTMaría de Toro
María de Toro
PVPaloma Menendez Valladares
Paloma Menendez Valladares
CGConcepción González-Rodriguez
Concepción González-Rodriguez
To evaluate the Bio-Rad D-100®, an HPLC analyzer for glycated hemoglobin (HbA1c) determination, and to compare its performance with the Menarini HA-8180V® and Sysmex G8®.

29 November 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
PGPaula García-Rodríguez
Paula García-Rodríguez
FMFeifei Ma
Feifei Ma
CRCarmen Del Rio
Carmen Del Rio
MRMarina Romero-Bernal
Marina Romero-Bernal
ANAna M. Najar
Ana M. Najar
JMJoan Montaner
Joan Montaner
Strokes are the second most common cause of death worldwide and a leading cause of disability. Regular consumption of polyphenols has been shown to reduce the risk of suffering a cardiovascular event. For this reason, we have investigated the protective effect of Salicornia ramosissima, a seasonal halophyte that synthetizes high amounts of bioactive compounds, including polyphenols, in response to environmental stress. Aqueous, hydroalcoholic, and ethanolic extracts were prepared to investigate if dietary supplementation prior to ischemic challenge can prevent subsequent damage using two animal models. First, we screened the protective effect against hypoxia–reoxygenation in Drosophila melanogaster and observed that both ethanolic and hydroalcoholic extracts protected flies from the deleterious effects of hypoxia. Second, we confirmed the protective effect of S. ramosissima ethanolic extract against brain ischemia using the transient middle cerebral artery occlusion mice model. Four weeks of oral supplementation with the ethanolic extract before artery occlusion reduced infarct volume and lowered the plasma levels of the DNA peroxidant product 8-hydroxydeoxyguanosine. Phytochemical profiling of S. ramosissima ethanolic extract revealed 50 compounds. Thus, it represents a valuable source of bioactive compounds that show promising disease-modifying activities and could be further developed as an effective food supplement for the prevention or treatment of neurovascular disorders.

1 July 2015 in Clinical Biochemistry
Verified
Journal Article
Closed access
PVPaloma Menendez Valladares
Paloma Menendez Valladares
PFPatricia Fernández-Riejos
Patricia Fernández-Riejos
CSCatalina Sánchez-Mora
Catalina Sánchez-Mora
APAntonio Pérez-Pérez
Antonio Pérez-Pérez
VSVíctor Sánchez-Margalet
Víctor Sánchez-Margalet
CGConcepción González-Rodríguez
Concepción González-Rodríguez